Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.

SP, Gampenrieder; V, Dezentjé; M, Lambertini; Nonneville A, de; M, Marhold; Du F, Le; Salgado A, Cortés; Costa D, Alpuim; Batista M, Vaz; Ruché N, Chic; C, Tinchon; A, Petzer; E, Blondeaux; Mastro L, Del; G, Targato; F, Bertucci; A, Gonçalves; F, Viret; R, Bartsch; C, Mannsbart; A, Deleuze; L, Robert; Serrano C, Saavedra; Cortés M, Gion; M, Sampaio-Alves; M, Vitorino; L, Pecen; C, Singer; N, Harbeck; G, Rinnerthaler; R, Greil

doi:10.1016/j.esmoop.2022.100747

Public

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.

Shared by NobleBlocks on Dec 21, 2022 • 12:00 AM UTC

Authors:

Gampenrieder SP

Dezentjé V

Lambertini M

Abstract

Background Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is...

Subject

Prognosis

Metastatic

Triple-negative Breast Cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!